Prognostic PET F-18-FDG Uptake Imaging Features Are Associated with Major Oncogenomic Alterations in Patients with Resected Non-Small Cell Lung Cancer

Division of Pulmonary & Critical Care Medicine, Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Cancer Research (Impact Factor: 9.28). 06/2012; 72(15):3725-34. DOI: 10.1158/0008-5472.CAN-11-3943
Source: PubMed

ABSTRACT Although 2[18F]fluoro-2-deoxy-d-glucose (FDG) uptake during positron emission tomography (PET) predicts post-surgical outcome in patients with non-small cell lung cancer (NSCLC), the biologic basis for this observation is not fully understood. Here, we analyzed 25 tumors from patients with NSCLCs to identify tumor PET-FDG uptake features associated with gene expression signatures and survival. Fourteen quantitative PET imaging features describing FDG uptake were correlated with gene expression for single genes and coexpressed gene clusters (metagenes). For each FDG uptake feature, an associated metagene signature was derived, and a prognostic model was identified in an external cohort and then tested in a validation cohort of patients with NSCLC. Four of eight single genes associated with FDG uptake (LY6E, RNF149, MCM6, and FAP) were also associated with survival. The most prognostic metagene signature was associated with a multivariate FDG uptake feature [maximum standard uptake value (SUV(max)), SUV(variance), and SUV(PCA2)], each highly associated with survival in the external [HR, 5.87; confidence interval (CI), 2.49-13.8] and validation (HR, 6.12; CI, 1.08-34.8) cohorts, respectively. Cell-cycle, proliferation, death, and self-recognition pathways were altered in this radiogenomic profile. Together, our findings suggest that leveraging tumor genomics with an expanded collection of PET-FDG imaging features may enhance our understanding of FDG uptake as an imaging biomarker beyond its association with glycolysis.


Available from: Olivier Gevaert, May 24, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-small-cell lung cancer is the most common type of lung cancer and one of the leading causes of cancer-related death worldwide. For this reason, advances in diagnosis and treatment are urgently needed. With the introduction of new, highly innovative hybrid imaging technologies such as PET/CT, staging and therapy response monitoring in lung cancer patients have substantially evolved. In this review, we discuss the role of FDG PET/CT in the management of lung cancer patients and the importance of new emerging imaging technologies and radiotracer developments on the path to personalized medicine.
    European journal of nuclear medicine and molecular imaging 01/2015; 42(4). DOI:10.1007/s00259-014-2974-5 · 5.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of multimodality imaging based on the use of positron emission tomography (PET) coupled to computerised tomography (CT) is continuously gaining ground in the field of oncology. The use of the technique in routine clinical practice is based on a visual interpretation or the determination of parameters such as the maximum standardised uptake value representing the highest activity voxel within the tumor. Other semi-quantitative parameters including the metabolic tumor volume and the total lesion glycolysis are increasingly used in the literature. More recently, alternative image derived parameters characterizing the tumor form and the heterogeneity in the intratumour activity distribution have been proposed. The objective of this article is to cover different aspects on these novel image derived indices, including: (i) the motivation behind their introduction and current use; (ii) obstacles in their utilization; (iii) methodological issues on their definition; (iv) their potential interest for future use in clinical practice.
    Medecine Nucleaire 04/2015; 39(3). DOI:10.1016/j.mednuc.2015.03.187 · 0.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Radiographic-imaging modalities like computerized tomography, positron emission tomography, and magnetic resonance imaging are playing a major role in the diagnosis and prognosis of cancer. Gene and protein expression patterns, from the tumor genome, are seen to facilitate individualized selection of therapies. Along with breakthroughs in biotechnology, applicable within cancer radiation biology, a new research field called Radiogenomics has been born in radiation oncology. Associating genotypes with imaging phenotypes holds promise for personalized optimal treatment. Segmentation and feature selection from the region of interest in an image are followed by correlation with the gene expression profile of the tumor in order to determine its noninvasive surrogates. This paper highlights the roles of quantitative imaging, genomics, and radiogenomics for a patient-specific tumor management.
    10/2014; 44(5):664-677. DOI:10.1109/THMS.2014.2325744